ESR1 and breast cancer: We found that in contrast to breast cancer samples from the ER-negative and Basal/Her2 subtypes, samples from the ER-positive/LumA-LumB subtypes showed weaker negative correlations (TCGA BRCA LumA/LumB: ALDOA vs. CD8A: r = -0.22, p = 2.0e-9; METABRIC ER-positive: ALDOA vs. CD3E: r = -0.24, p = 1.24e-20) (Supp Figures S1A, B).